Ionis Pharmaceuticals, Inc. - Common Stock (IONS)
33.50
+0.18 (0.54%)
Ionis Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development ofRNA-targeted therapies
By leveraging its proprietary antisense technology, Ionis focuses on treating a range of serious diseases, including neurological disorders, cardiovascular conditions, and rare diseases. The company's innovative approach allows for precise targeting of specific genes to modulate protein production, providing potential treatment options for patients with unmet medical needs. With a robust pipeline of therapies in various stages of clinical development, Ionis is dedicated to advancing the field of genetic medicine and improving patient outcomes.
Previous Close | 33.32 |
---|---|
Open | 32.50 |
Bid | 33.47 |
Ask | 33.53 |
Day's Range | 31.90 - 33.77 |
52 Week Range | 31.40 - 52.49 |
Volume | 839,964 |
Market Cap | 4.75B |
PE Ratio (TTM) | -22.95 |
EPS (TTM) | -1.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 1,540,616 |
News & Press Releases
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA
By Biogen Inc. · Via GlobeNewswire · January 23, 2025
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Expertsbenzinga.com
Via Benzinga · January 15, 2025
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.investors.com
One analyst says the six-month study was too short and the benefits could appear over time.
Via Investor's Business Daily · January 7, 2025
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expectedbenzinga.com
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.
Via Benzinga · January 7, 2025
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Expertsbenzinga.com
Via Benzinga · December 20, 2024
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analystsbenzinga.com
Via Benzinga · November 7, 2024
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimisticbenzinga.com
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Via Benzinga · January 3, 2025
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Bloodbenzinga.com
Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.
Via Benzinga · December 20, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · November 12, 2024
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500benzinga.com
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.
Via Benzinga · October 31, 2024
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)benzinga.com
Via Benzinga · September 26, 2024
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticalsbenzinga.com
Via Benzinga · August 26, 2024
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Upinvestors.com
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via Investor's Business Daily · October 18, 2024
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from Part B and Part C of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of an investigational higher dose regimen of nusinersen in spinal muscular atrophy (SMA), showing benefits in both individuals previously treated and treatment-naïve to nusinersen with infantile-onset or later-onset SMA. The investigational, higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA®). Data to be presented during the World Muscle Society (WMS) 2024 Congress (Oct. 8-12, 2024 in Prague) highlight the potential of this investigational higher dose regimen to help address remaining unmet need in SMA.
By Biogen Inc. · Via GlobeNewswire · October 8, 2024
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · September 10, 2024
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analystsbenzinga.com
Via Benzinga · June 27, 2024
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · September 10, 2024
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · September 4, 2024
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA). The investigational higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the approved nusinersen regimen (SPINRAZA). The study met its primary endpoint at six months, achieving a statistically significant improvement in motor function in infants who received the higher dose regimen as compared to a prespecified matched sham (untreated) control group from the ENDEAR study.
By Biogen Inc. · Via GlobeNewswire · September 4, 2024
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analystbenzinga.com
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety profile is favorable. Phase 3 study planned for 2025.
Via Benzinga · July 22, 2024
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wronginvestors.com
Biogen previously decided against opting into Ionis' Angelman program.
Via Investor's Business Daily · July 22, 2024